Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Fiche publication
Date publication
septembre 2016
Journal
Clinical colorectal cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E, Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T,
Lien Pubmed
Résumé
5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC.
Mots clés
Adjuvant chemotherapy, CVAD, Colon cancer, Peripheral venous access, XELOX
Référence
Clin Colorectal Cancer. 2016 Sep;15(3):250-6